Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study

Introduction: An increasing amount of evidence indicates that platelet reactivity, despite a standard anti-thrombotic therapy, is a potential risk factor for recurrent myocardial ischemia in patients with coronary artery disease. We now hypothesize that this condition, measured by collagen--epinephrine (CEPI) or collagen--ADP (CADP) closure times (CT) by Platelet Function Analyzer (PFA-100), may predict the recurrence of coronary events after percutaneous coronary intervention (PCI). Materials and methods: CEPI and CADP-CT were measured 30F8 h after PCI in 175 consecutive patients admitted with a diagnosis of stable angina (n =94) or acute coronary syndromes (n =81) and prospectively followed up for a mean period of 6 months. We stratified the patients in accordance to both the CEPI-CT (borN 190 s), reflecting the intensity of cycloxygenase inhibition by aspirin and the distribution into quartiles for CADP-CT. Results: CEPI-CTb190 s as well as CADP-CTb82 s were associated with a higher rate of clinical recurrence (hazard ratio 8.5, p b0.001 and 22.9, p b0.001, respectively). Multivariate analysis after adjustment for other risk factors confirmed that the lowest CADP-CT quartile significantly correlates with the risk of recurrent coronary events (hazard ratio 36.5, p b0.01), as well as CEPI-CTb190 s (hazard ratio 6.7, p =0.01).